Literature DB >> 1647520

Sequence requirements for mammalian topoisomerase II mediated DNA cleavage stimulated by an ellipticine derivative.

P Fossé1, B René, M Le Bret, C Paoletti, J M Saucier.   

Abstract

Various antitumor drugs stabilize DNA topoisomerase II-DNA transient covalent complexes. The complexes distribution along pBR322 DNA was shown previously to depend upon the nature of the drug (Tewey et al. (1984) Science 226, 466-468). The position in pBR322 of DNA cleavage by calf DNA topoisomerase II for 115 such sites stabilized by an ellipticine derivative and the relative frequency of cleavage at most of these sites were determined. The nucleotide sequence surrounding the 25 strongest sites was analyzed and the following ellipticine specific consensus sequence was deduced: 5'-ANCNT(A/G)T.NN(G/C)N(A/G)-3' where cleavage occurs at the indicated mark. A thymine is always present at the 3' end of at least one strand of the strong cleavage sites, and the dinucleotide AT or GT at the 3' end of the break plays a major role in the complex stabilisation. The predictive value of cleavage of the consensus was tested for two regions of SV40 DNA and cleavage was indeed detected at the majority of the sites matching the consensus. Some complexes stabilized by ellipticine are resistant to salt dissociation and this property seems to be correlated with the presence of symmetrical sequences in the cleavage site with a center of symmetry staggered relatively to the center of symmetry of cleavage.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1647520      PMCID: PMC328243          DOI: 10.1093/nar/19.11.2861

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  28 in total

1.  Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide.

Authors:  N Osheroff
Journal:  Biochemistry       Date:  1989-07-25       Impact factor: 3.162

Review 2.  Topoisomerase-targeting antitumor drugs.

Authors:  P D'Arpa; L F Liu
Journal:  Biochim Biophys Acta       Date:  1989-12-17

3.  DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II.

Authors:  T C Rowe; G L Chen; Y H Hsiang; L F Liu
Journal:  Cancer Res       Date:  1986-04       Impact factor: 12.701

4.  Information content of binding sites on nucleotide sequences.

Authors:  T D Schneider; G D Stormo; L Gold; A Ehrenfeucht
Journal:  J Mol Biol       Date:  1986-04-05       Impact factor: 5.469

5.  A consensus sequence for cleavage by vertebrate DNA topoisomerase II.

Authors:  J R Spitzner; M T Muller
Journal:  Nucleic Acids Res       Date:  1988-06-24       Impact factor: 16.971

Review 6.  Topoisomerase II as a target of anticancer drug action in mammalian cells.

Authors:  K W Kohn; Y Pommier; D Kerrigan; J Markovits; J M Covey
Journal:  NCI Monogr       Date:  1987

7.  Protein-associated deoxyribonucleic acid strand breaks produced in mouse leukemia L1210 cells by ellipticine and 2-methyl-9-hydroxyellipticinium.

Authors:  L A Zwelling; S Michaels; D Kerrigan; Y Pommier; K W Kohn
Journal:  Biochem Pharmacol       Date:  1982-10-15       Impact factor: 5.858

8.  Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II.

Authors:  J Markovits; C Linassier; P Fossé; J Couprie; J Pierre; A Jacquemin-Sablon; J M Saucier; J B Le Pecq; A K Larsen
Journal:  Cancer Res       Date:  1989-09-15       Impact factor: 12.701

9.  Nuclease protection by Drosophila DNA topoisomerase II. Enzyme/DNA contacts at the strong topoisomerase II cleavage sites.

Authors:  M P Lee; M Sander; T Hsieh
Journal:  J Biol Chem       Date:  1989-12-25       Impact factor: 5.157

10.  DNA topoisomerase II cleaves at specific sites in the 5' flanking region of c-fos proto-oncogenes in vitro.

Authors:  M K Darby; R E Herrera; H P Vosberg; A Nordheim
Journal:  EMBO J       Date:  1986-09       Impact factor: 11.598

View more
  14 in total

1.  General method of preparation of uniformly 13C, 15N-labeled DNA fragments for NMR analysis of DNA structures.

Authors:  Brigitte René; Grégoire Masliah; Loussiné Zargarian; Olivier Mauffret; Serge Fermandjian
Journal:  J Biomol NMR       Date:  2006-10-04       Impact factor: 2.835

2.  A novel topoisomerase II poison GL331 preferentially induces DNA cleavage at (C/G)T sites and can cause telomere DNA damage.

Authors:  C C Lee; T S Huang
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

Review 3.  DNA topoisomerase I and II in cancer chemotherapy: update and perspectives.

Authors:  Y Pommier
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

4.  Base mutation analysis of topoisomerase II-idarubicin-DNA ternary complex formation. Evidence for enzyme subunit cooperativity in DNA cleavage.

Authors:  M Bigioni; F Zunino; G Capranico
Journal:  Nucleic Acids Res       Date:  1994-06-25       Impact factor: 16.971

Review 5.  Structure and function of type II DNA topoisomerases.

Authors:  P M Watt; I D Hickson
Journal:  Biochem J       Date:  1994-11-01       Impact factor: 3.857

6.  Hairpins in a DNA site for topoisomerase II studied by 1H- and 31P-NMR.

Authors:  A Amir-Aslani; O Mauffret; P Bittoun; F Sourgen; M Monnot; E Lescot; S Fermandjian
Journal:  Nucleic Acids Res       Date:  1995-10-11       Impact factor: 16.971

7.  Transient dsDNA breaks during pre-replication complex assembly.

Authors:  Emmanouil Rampakakis; Maria Zannis-Hadjopoulos
Journal:  Nucleic Acids Res       Date:  2009-07-28       Impact factor: 16.971

8.  Localization of an aminoacridine antitumor agent in a type II topoisomerase-DNA complex.

Authors:  C H Freudenreich; K N Kreuzer
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

9.  Phosphorus-31 transverse relaxation rate measurements by NMR spectroscopy: insight into conformational exchange along the nucleic acid backbone.

Authors:  Laurent J Catoire
Journal:  J Biomol NMR       Date:  2004-02       Impact factor: 2.835

10.  Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites.

Authors:  Y Pommier; G Kohlhagen; K W Kohn; F Leteurtre; M C Wani; M E Wall
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.